Journal of the American Heart Association, Volume 15, Issue 6 , March 17, 2026. BackgroundNeuroprotective strategies as primary or ancillary treatment could ameliorate the significant mortality and disability associated with ischemic stroke.
Nanoliposomes composed of monosialoganglioside, phosphatidylcholine, and cholesterol (NLGM1) were previously shown to ameliorate brain injury when given before arterial occlusion in mice. We aimed to test the hypothesis that NLGM1 given following transient intraluminal filament and photothrombotic (PT) middle cerebral artery occlusion (MCAO) will attenuate acute and chronic stroke injury in mice.MethodsTwelve‐week‐old C57BL/6 mice underwent MCAO for 45 minutes and were then injected with 1 or 3 doses of saline or NLGM1 (1 or 2 mg IV) after occlusion.
Neurologic deficit score and brain infarct area were measured after 48 hours. Separate mice underwent PT occlusion of the distal lateral middle cerebral artery trunk followed by injection of 1 or 2 doses saline or NLGM1 (1 or 2 mg IV) postocclusion.
Journal of the American Heart Association published a clinical update in Cardiology on 10 Mar 2026.
The item focuses on Monosialoganglioside‐Containing Nanoliposomes Protect Against Acute and Chronic Ischemic Stroke Injury.
Review the original article for the full source wording and details.